1. Home
  2. SFNC vs MLYS Comparison

SFNC vs MLYS Comparison

Compare SFNC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Simmons First National Corporation

SFNC

Simmons First National Corporation

HOLD

Current Price

$19.28

Market Cap

2.8B

Sector

Finance

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$37.32

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SFNC
MLYS
Founded
1903
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.1B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
SFNC
MLYS
Price
$19.28
$37.32
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$22.75
$47.33
AVG Volume (30 Days)
1.1M
1.6M
Earning Date
01-20-2026
11-10-2025
Dividend Yield
4.41%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$27.12
N/A
Revenue Next Year
$7.58
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.00
$8.24
52 Week High
$23.44
$47.65

Technical Indicators

Market Signals
Indicator
SFNC
MLYS
Relative Strength Index (RSI) 56.93 43.48
Support Level $19.01 $36.01
Resistance Level $19.83 $39.15
Average True Range (ATR) 0.41 1.81
MACD 0.04 -0.16
Stochastic Oscillator 52.86 31.53

Price Performance

Historical Comparison
SFNC
MLYS

About SFNC Simmons First National Corporation

Simmons First National Corp is a financial holding company. The company through its subsidiaries is engaged in providing banking services including consumer, real estate and commercial loans, checking, savings and time deposits. The company's loan portfolio comprises construction, single-family residential and commercial loans; non-real estate loans, nonaccrual and past due loans; and credit card loans, student loans and other consumer loans. It also offers various products and services such as trust services, investments, agricultural finance lending, equipment lending, insurance, consumer finance and small business administration lending. The business activity of the firm is functioned through the region of the United States.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: